RXRX director granted 3,747 Class A shares

Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.

RECURSION PHARMACEUTICALS, INC. director Dean Y. Li reported an equity award of Class A Common Stock. He received 3,747 shares at $0.0000 per share as compensation under the company’s Outside Director Compensation Policy, increasing his direct holdings to 1,473,329 Class A shares.

In addition to these direct holdings, he is also shown as indirectly holding 421,000 Class A shares through the Dean Y. Li 2021 Family Trust and 1,422,048 Class A shares through the Dean Y. Li Revocable Trust.

Insider Trade Summary

Grant/Award: 3,747 shares

Grant/Award 3 txns

Insider Li Dean Y

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	3,747	$0.00	$0.00
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,473,329 shares (Direct); Class A Common Stock — 1,422,048 shares (Indirect, By Dean Y. Li Revocable Trust); Class A Common Stock — 421,000 shares (Indirect, By Dean Y. Li 2021 Family Trust)

Footnotes (1)

1. F1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Key Figures

Equity award: 3,747 shares Grant price: $0.0000 per share Direct holdings after grant: 1,473,329 shares +2 more

5 metrics

Equity award 3,747 shares Class A Common Stock granted at $0.0000 per share

Grant price $0.0000 per share Price for 3,747 Class A shares under director policy

Direct holdings after grant 1,473,329 shares Class A Common Stock held directly after transaction

Family Trust holdings 421,000 shares Class A shares held by Dean Y. Li 2021 Family Trust

Revocable Trust holdings 1,422,048 shares Class A shares held by Dean Y. Li Revocable Trust

Key Terms

Outside Director Compensation Policy, Class A Common Stock, Revocable Trust, Family Trust

4 terms

Outside Director Compensation Policy financial

"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."

Class A Common Stock financial

"The transactions involve shares of Class A Common Stock of Recursion Pharmaceuticals."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Revocable Trust financial

"Shares are indirectly held by the Dean Y. Li Revocable Trust."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Family Trust financial

"Shares are indirectly held by the Dean Y. Li 2021 Family Trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RXRX director Dean Y. Li report in this Form 4 filing?

Dean Y. Li reported receiving an equity award of 3,747 shares of Recursion Pharmaceuticals Class A Common Stock at $0.0000 per share as compensation under the company’s Outside Director Compensation Policy, increasing his directly held position.

How many RXRX shares did Dean Y. Li receive as compensation?

He received 3,747 Class A Common Stock shares of Recursion Pharmaceuticals. The shares were issued at $0.0000 per share under the company’s Outside Director Compensation Policy, indicating a compensation-related grant rather than an open-market purchase.

What are Dean Y. Li’s direct RXRX holdings after this reported transaction?

Following the equity award, Dean Y. Li directly holds 1,473,329 shares of Recursion Pharmaceuticals Class A Common Stock. This total reflects the new grant of 3,747 shares issued at $0.0000 per share as part of his director compensation.

What indirect RXRX shareholdings are associated with Dean Y. Li’s trusts?

The filing shows 421,000 Class A shares held by the Dean Y. Li 2021 Family Trust and 1,422,048 Class A shares held by the Dean Y. Li Revocable Trust, both reported as indirect holdings of Recursion Pharmaceuticals stock.

Was the RXRX share grant to Dean Y. Li an open-market purchase?

No, it was not an open-market purchase. The 3,747 Class A shares were issued at $0.0000 per share pursuant to Recursion Pharmaceuticals’ Outside Director Compensation Policy, indicating a compensation-related grant rather than a market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Li Dean Y

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/01/2026		A(1)		3,747	A	$0	1,473,329	D
Class A Common Stock								1,422,048	I	By Dean Y. Li Revocable Trust
Class A Common Stock								421,000	I	By Dean Y. Li 2021 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)